Clik here to view.
New Antimicrobial Drugs: EU Policy Options
Pryia Sharma Antimicrobial resistance (AMR) to drugs, a natural and unavoidable consequence of treating infectious diseases, is a growing global public health threat. AMR reduces the chances of...
View ArticleClik here to view.
New: Antimicrobial Drug Incentives
OHE has just made available Research Paper 11/02, Incentives for New Antimicrobial Drugs. Antimicrobial resistance (AMR) is becoming a major global public health threat and has begun to command...
View ArticleClik here to view.
News Release: Fighting Superbugs
Report recommends new ways to boost R & D in fight against superbugs A new report today by the Office of Health Economics (OHE) called for a shake up in the way future antibiotics are to be...
View ArticleClik here to view.
Incentives for R&D for New Antimicrobial Drugs
Sharma and Towse Just published by OHE researchers is a comprehensive analysis* of what policy measures are needed to counter the growing global problem of antimicrobial resistance. Their key findings...
View ArticleClik here to view.
Antibacterials: Roundtable Addresses the Critical Issues
Antibacterial drug resistance is a serious and growing worldwide problem that threatens our ability to cure traditionally treatable diseases and to successfully perform numerous surgical procedures...
View ArticleOHE Models Incentives for Antibiotic Drug Development
A new model aimed at encouraging the development of new antibiotics was presented[1] recently by OHE’s Chris Hoyle, who collaborated with Adrian Towse and Jorge Mestre-Ferrandiz in designing the model....
View ArticleSpotlight on OHE: Innovation, Regulation and Antibiotics
OHE long has been involved in analysing the nature of innovation and the effects of regulation. Two recent OHE presentations address the core issues. Incentives for innovation in antibiotics The...
View Article
